Cannabinoid Receptor Modulators, Their Processes Of Preparation, And Use Of Cannabinoid Receptor Modulators For Treating Respiratory And Non-Respiratory Diseases
Katerina Leftheris - Skillman NJ Hong Wu - Lawrenceville NJ Stephen Wrobleski - Whitehouse Station NJ Ping Chen - Belle Mead NJ John Hynes - Washington Crossing PA John Tokarski - Princeton NJ
Assignee:
Bristol-Myers Squibb Co. - Princeton NJ
International Classification:
C07D40312
US Classification:
5142328, 514292, 544126, 546 81
Abstract:
Use of a compound for treating a respiratory disease in a mammal wherein the compound is a cannabinoid receptor modulator is disclosed. Compounds useful as cannabinoid receptor modulators for treating respiratory and non-respiratory leukocyte-activation associated diseases comprise compounds of formula (I), in which A and B are nitrogen or carbon, provided only one of A and B is nitrogen; and R -R are as defined in the specification, wherein R with R may form a ring, and/or two R groups may form a six-membered aryl or heteroaryl ring, optionally having a substituent R forming a ring with R.
Fused Heterocyclic Compounds Useful As Kinase Modulators
Wayne Vaccaro - Yardley PA, Zhong Chen - Princeton NJ, Dharmpal S. Dodd - Princeton NJ, Tram N. Huynh - Pennington NJ, James Lin - Lawrenceville NJ, Chunjian Liu - Pennington NJ, Christopher P. Mussari - Princeton NJ, John S. Tokarski - Princeton NJ, David R. Tortolani - Skillman NJ, Stephen T. Wrobleski - Whitehouse Station NJ, Shuqun Lin - Newtown PA,
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
C07D 487/04 A61K 31/5025 A61P 19/02
US Classification:
514248, 544236
Abstract:
Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof,.
Pyrrolopyridazine Jak3 Inhibitors And Their Use For The Treatment Of Inflammatory And Autoimmune Diseases
Stephen T. Wrobleski - Flemington NJ, Jagabandhu Das - Mercerville NJ, Lidia M. Doweyko - Vero Beach FL, Junqing Guo - Princeton NJ, John Hynes - Washington Crossing PA, Bin Jiang - Norristown PA, James Kempson - Princeton NJ, Shuqun Lin - Newtown PA, Steven H. Spergel - Warrington PA, John S. Tokarski - Princeton NJ, Hong Wu - New Hope PA, Bingwei Vera Yang - Belle Mead NJ,
Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.
Brian E. Fink - Yardley PA, Ashvinikumar V. Gavai - Princeton Junction NJ, Gregory D. Vite - Titusville NJ, Ping Chen - Belle Mead NJ, Harold Mastalerz - Guilford CT, Derek J. Norris - Pennington NJ, John S. Tokarski - Princeton NJ, Yufen Zhao - Pennington NJ, Wen-Ching Han - Newtown PA,
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof.The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
T315A And F317I Mutations Of Bcr-Abl Kinase Domain
Charles L. Sawyers - Los Angeles CA, Michael Burgess - Los Angeles CA, Neil Pravin Shah - Los Angeles CA, Francis Y. Lee - Yardley PA, John S. Tokarski - Princeton NJ, Herbert E. Klei - Lawrenceville NJ,
International Classification:
A61K 31/497 C12Q 1/48 G01N 33/53 C12Q 1/68
US Classification:
51425219, 435 15, 435 71, 435 6
Abstract:
The present invention relates to mutant BCR-ABL kinase proteins, and to diagnostic and therapeutic methods and compositions useful in the management of disorders, for example cancers, involving cells that express such mutant BCR-ABL kinase proteins.
Fused Heterocyclic Compounds Useful As Kinase Modulators
Compounds having the formula (1), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof,
are usefuil as kinase modulators, including MK2 modulation, wherein one of E and F is a nitrogen atom and the other of E and F is a carbon atom, Z is N or CR, and R, R, R, X and Y are as defined herein.
Brian E. Fink - Princeton Junction NJ, Ashvinikumar V. Gavai - Princeton Junction NJ, Gregory D. Vite - Titusville NJ, Ping Chen - Belle Mead NJ, Harold Mastalerz - Guilford CT, Derek J. Norris - Pennington NJ, John S. Tokarski - Princeton NJ, Yufen Zhao - Pennington NJ, Wen-Ching Han - Newtown PA,
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 31/53 A61P 35/00 C07D 401/06 C07D 401/14
US Classification:
514243, 544183
Abstract:
The present invention provides compounds of formula IThe formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.